Inclusion of Older Patients with Cancer in Clinical Trials: The SAGE Prospective Multicenter Cohort Survey.
Florence Canouï-PoitrineAstrid LièvreFlorent DaydeDaniel Lopez-Trabada-AtazIsabelle BaumgaertnerOlivier DubreuilFrancesco BrunettiRomain CoriatKarin MaleySimon PernotChristophe TournigandMeoin HagegeThomas AparicioElena PaillaudSylvie Bastuji-GarinPublished in: The oncologist (2019)
The results of this study suggest that barriers to participation of older patients in clinical trials are particularly marked at age 80 years or older. Secondly, the results emphasize the need for trials for older patients. Thirdly, there is also a need for more pragmatic "real-world" trials, rather than solely randomized trials performed in idealized settings with strictly selected patients. Large prospective observational cohorts with a precise follow-up of toxicity, functional decline, and quality of life may constitute one way of generating more data on the risk-benefit ratio for cancer treatments in older patients.
Keyphrases
- clinical trial
- physical activity
- end stage renal disease
- cross sectional
- ejection fraction
- newly diagnosed
- chronic kidney disease
- community dwelling
- middle aged
- oxidative stress
- electronic health record
- study protocol
- big data
- squamous cell carcinoma
- randomized controlled trial
- open label
- squamous cell
- machine learning
- deep learning
- young adults
- phase iii